ROCHE I/ CH0012032113 /
2024-05-16 5:30:31 PM | Chg. +8.00 | Volume | Bid7:16:36 PM | Ask7:16:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
256.80CHF | +3.22% | 39,828 Turnover: 10.24 mill. |
-Bid Size: 170 | -Ask Size: 5 | 217.41 bill.CHF | 3.70% | 17.83 |
GlobeNewswire
1:00 PM
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
GlobeNewswire
05-15
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
05-14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
04-03
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-22
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
03-14
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
02-26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
02-21
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
GlobeNewswire
02-13
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Busine...
GlobeNewswire
01-30
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha ...
GlobeNewswire
01-03
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
01-03
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
2023-12-29
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche